Business Wire

Sonitor Technologies Wins Patent Dispute With CenTrak

Del

Sonitor Technologies, a global leader in indoor, ultrasound-based positioning technologies today announced that is has won its patent dispute with CenTrak. In a decision dated August 30, 2017, the United States District Court in Delaware ruled that Sonitor does not infringe CenTrak’s U.S. Patent No. 8,604,909, and that CenTrak’s patent is invalid.

CenTrak had sued Sonitor in February 2014, accusing the Sonitor Sense™ products of infringement of that patent. The court first found that there was no evidence to support a finding of infringement by Sonitor. The court also held that Sonitor had demonstrated that all claims of CenTrak’s patent are invalid because the patent does not disclose an ultrasonic real-time location system (RTLS), noting that ultrasound is “fundamentally different” than the CenTrak infrared technology disclosed in the patent.

“We are extremely pleased with the Court’s decision and have always believed that we would prevail in this case,” said Arne Oyen, Group President & CEO at Sonitor Technologies AS. Anne Bugge, President and CEO, Sonitor Technologies, Inc. added, “This decision solidifies and further vindicates and supports our leading position in ultrasound-based indoor positioning and RTLS.”

About Sonitor Technologies

Sonitor Technologies is a leading provider of Real Time Location System (RTLS) solutions linking the physical world with the Internet of Things (IoT) to provide real-time visibility and connected intelligence. As the first and only company to use proprietary ultrasound technology as the primary technology for indoor positioning systems (IPS), Sonitor’s platform automatically tracks the real-time location of moveable equipment and people with 100% room or sub-room level accuracy in complex, indoor environments, such as hospitals, clinics and ambulatory surgery centers. With an open integration platform, Sonitor provides the flexibility to leverage best-in-class software application solutions covering many uses such as nurse call, patient flow, workflow and capacity management, hand hygiene and infection control and asset and inventory management.

Contact information

Beacon Communications
Dan Conley, 312-593-8461
dconley@beaconpr.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Bacardi to Acquire Patrón Tequila22.1.2018 20:28Pressemelding

Family-owned Bacardi Limited, the largest privately held spirits company in the world, announced today that it is expanding its portfolio of premium spirits with a definitive agreement to acquire 100% ownership of Patrón Spirits International AG and its PATRÓN® brand, the world’s top-selling ultra-premium tequila. The transaction, which is subject to customary closing conditions, follows the successful relationship the companies have had for nearly a decade since Bacardi’s initial acquisition of a significant minority stake in Patrón in 2008. The transaction reflects an enterprise value for Patrón of US$5.1 billion and is expected to close in the first half of 2018. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122006459/en/ Bacardi agrees to acquire 100% ownership of Patrón Spirits International and its PATRÓN® brand, the world’s top-selling ultra-premium tequila. (Photo: Business Wire) According to the most recent IWSR

PMI’s Salary Survey Reveals that Project Management Practitioners with the PMP Certification Earn 23% More22.1.2018 16:58Pressemelding

Project Management Institute’s (PMI) Earning Power Report reveals a significant advantage in earning potential for PMP® certified practitioners. Survey respondents holding the Project Management Professional (PMP)® certification report higher median salaries than those without a PMP certification―23% higher on average across the 37 countries surveyed. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122006262/en/ (Graphic: Business Wire) The Earning Power: Project Management Salary Survey is a comprehensive biennial salary survey that offers insight into the value of project management skills, experience and certifications. It is an industry-leading source of data, giving project management practitioners a greater awareness of their earning potential and helping employers, compensation committees, human resource departments and executive recruiters to better determine salary ranges. The 10th edition of the survey incorporate

ABB and City of Davos Pave the Way to Sustainable Mobility Through E-Vehicle Innovation22.1.2018 15:41Pressemelding

For this year’s annual World Economic Forum (January 23–26, 2018), the city of Davos and ABB have teamed up in a long-term partnership to provide e-infrastructure for public and private transportation. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122006126/en/ ABB flash-charging station in Davos (Photo: Business Wire) Davos residents and WEF guests can experience the pioneering TOSA bus for themselves. The award-winning TOSA bus, developed by ABB in Switzerland, is already in use in Geneva and will soon be implemented in the French city of Nantes. It can recharge its battery in just 20 seconds as passengers board and disembark. In Davos, it will operate on the busy Line 1, running from the tourist center to the hospital. This is the first time TOSA technology is being used in an Alpine region. The idea is to run the system under extreme winter weather conditions; ABB and its project partners expect to gain valuable insig

Calvin Klein, Inc. Announces the Spring/Summer 2018 Calvin Klein Underwear and Calvin Klein Jeans Global Advertising Campaign22.1.2018 14:00Pressemelding

Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE:PVH], today announced its new CALVIN KLEIN UNDERWEAR and CALVIN KLEIN JEANS global multi-media advertising campaign. The campaign represents the latest iteration of the evolution in the CALVIN KLEIN brand’s globally recognized #MYCALVINS call to action: Our Family. #MYCALVINS. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122005732/en/ CALVIN KLEIN, INC. ANNOUNCES THE SPRING/SUMMER 2018 Campaign Led by Kim Kardashian West, Khloé Kardashian, Kourtney Kardashian, Kendall Jenner and Kylie Jenner Shot by photographer Willy Vanderperre, the latest chapter of this new campaign features sisters Kim Kardashian West, Khloé Kardashian, Kourtney Kardashian, Kendall Jenner and Kylie Jenner. The siblings are featured wearing styles of CALVIN KLEIN UNDERWEAR that are available in stores and online now, including CALVIN KLEIN Modern Cotton and the new CALVIN KLEIN Body ran

Ferring enters into worldwide OmniAb® platform license agreement with Ligand22.1.2018 14:00Pressemelding

Ferring Pharmaceuticals announced today that it has entered into a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform® to discover new human monoclonal antibodies for a range of indications. Under the agreement, Ferring will use OmniAb to accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology. “Antibody-based therapies improve the quality of life and care for patients with a wide range of conditions but have not been fully investigated, in particular in the area of reproductive medicine and women’s health,” said Armin Metzger, Senior Vice President, Head of Global Pharmaceutical Research and Development, Ferring Pharmaceuticals. “This agreement expands Ferring’s growing capabilities in biologics and broadens our historical focus on peptides, opening up significant opportunities for discoveries that will help patients to live better lives.” Ligand's OmniAb® platforms produce

European Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients22.1.2018 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) extended the current conditional marketing authorization of ADCETRIS® (brentuximab vedotin) and approved ADCETRIS for the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, which is expressed on skin lesions in approximately 50 percent of patients with CTCL. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on November 9, 2017. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122005037/en/ “CTCL is a subtype of non-Hodgkin lymphoma that primarily involves the skin; it typically presents with red, scaly patches or thickened plaques of skin that often mimics eczema or psoriasis and can have a substantial impact on patients’ self-esteem. There a

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom